John J McCabe, Cathal Walsh, Sarah Gorey, Katie Harris, Pablo Hervella, Ramon Iglesias-Rey, Christina Jern, Linxin Li, Nobukazu Miyamoto, Joan Montaner, Annie Pedersen, Francisco F Purroy, Peter M Rothwell, Cathie L Sudlow, Yuji Ueno, Mikel Vicente-Pascual, Will N Whiteley, Mark Woodward, Peter J Kelly
BACKGROUND AND OBJECTIVES: Anti-inflammatory therapies reduce major adverse cardiovascular events (MACE) in coronary artery disease but remain unproven after stroke. Establishing the subtype-specific association between inflammatory markers and recurrence risk is essential for optimal selection of patients in randomized trials (RCTs) of anti-inflammatory therapies for secondary stroke prevention. METHODS: Using individual participant data (IPD) identified from a systematic review, we analyzed the association between high-sensitivity C-reactive protein, interleukin-6 (IL-6), and vascular recurrence after ischemic stroke or transient ischemic attack...
January 23, 2024: Neurology